百利天恒：《药物临床试验批准通知书》

每日经济新闻07-11

每经AI快讯，百利天恒（SH 688506，收盘价：161.98元）7月11日晚间发布公告称，四川百利天恒药业股份有限公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1（ADC）的药物临床试验获得批准。2023年1至12月份，百利天恒的营业收入构成为：医药制造业占比99.74%。截至发稿，百利天恒市值为650亿元。道达号（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450337456?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-11 18:36","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2450337456","market":"sh","top_or_hot":-1,"title":"百利天恒： 《药物临床试验批准通知书》","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，百利天恒（SH 688506，收盘价：161.98元）7月11日晚间发布公告称，四川百利天恒药业股份有限公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1（ADC）的药物临床试验获得批准。2023年1至12月份，百利天恒的营业收入构成为：医药制造业占比99.74%。截至发稿，百利天恒市值为650亿元。道达号（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒： 《药物临床试验批准通知书》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒： 《药物临床试验批准通知书》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-11 18:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，百利天恒（SH 688506，收盘价：161.98元）7月11日晚间发布公告称，四川百利天恒药业股份有限公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1（ADC）的药物临床试验获得批准。2023年1至12月份，百利天恒的营业收入构成为：医药制造业占比99.74%。截至发稿，百利天恒市值为650亿元。道达号（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b","article_id":"2450337456","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2450337456","pubTimestamp":1720694208,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"每经AI快讯，百利天恒 7月11日晚间发布公告称，四川百利天恒药业股份有限公司于近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1的药物临床试验获得批准。2023年1至12月份，百利天恒的营业收入构成为：医药制造业占比99.74%。截至发稿，百利天恒市值为650亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688506":"百利天恒","BK0239":"医药制造"},"translate_title":"Baili Tianheng: \"Notice of Approval of Drug Clinical Trial\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":1},"content_text":"每经AI快讯，百利天恒（SH 688506，收盘价：161.98元）7月11日晚间发布公告称，四川百利天恒药业股份有限公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1（ADC）的药物临床试验获得批准。2023年1至12月份，百利天恒的营业收入构成为：医药制造业占比99.74%。截至发稿，百利天恒市值为650亿元。道达号（daoda1997）“个股趋势”提醒：1. 百利天恒-U近30日内北向资金持股量减少208.56万股，占流通股比例减少2.30%；2. 近30日内无机构对百利天恒-U进行调研。每经头条（nbdtoutiao）——格力：诉小米风扇侵权案胜诉，获赔185万元！小米：未收到任何环境电器相关诉讼，格力再回应(记者 曾健辉)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450337456"}

百利天恒： 《药物临床试验批准通知书》

精彩评论

百利天恒：《药物临床试验批准通知书》